Saeid Akhtari

We are building the largest longitudinal cohort in the Americas to power precision health at scale for all. Our goal is to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. We are focused on Latin America and our diaspora populations throughout the world including founder populations in the Americas, those who identify as Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander as well as people who self identify as belonging to two or more of these groups. Core to our mission is building trust with the communities we serve and long term partnerships with communities, researchers, clinicians, and most of all patients and their families. This is your biobank and for the benefit of all. If we build it, we can decide how the data are used. And no one is going to do it for us, so let’s roll up our sleeves and “time to build.” Join us! Este biobanco es tuyo y para todo el continente porque si lo construimos juntos podemos decidir cómo se usan los datos y con que fines. Nadie lo va a hacer por nosotros así que bienvenido a nuestro esfuerzo. Unete!

Healthcare data is messy. We all know it. Datasets are often riddled with errors, inconsistencies and missing values, requiring data science teams to spend countless hours cleaning data before analyzing it. The Cornerstone AI assistant is purpose-built to clean RWD. Its proprietary machine learning models automatically generate unique clinically relevant data cleaning rules for every dataset. The Cornerstone AI assistant learns the structure and connections across data sources, harmonizing the structure. ML models then identify and correct errors, which are applied automatically or guided through our UI for optimal balance of scalability and nuance.

Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.

Gencove creates high-volume, cost-sensitive sequencing software-as-a-service to help academic, agriculture, biotech, diagnostic, and pharmaceutical companies get all the genomic information they need to make life-saving discoveries.

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.

PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver first-in-class test products that enable early disease detection and treatment. Powerful, Untapped Disease Insights Built on a Proteomics Foundation: Until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next generation tools that can elucidate complex proteomics at scale. Complementary Molecular Information: Genomic data has made clear contributions to researchers’ abilities to understand and more precisely treat disease, but it is has shown limited impact on early-stage disease detection. Proteomics provides direct information on the biological state of a cell, including disease at its earliest state, but proteomics data has been technically difficult to generate – until now. By complementing the new sources of proteomics data with genomics and other data, such as metabolomics, we now have the tools to generate powerful multi-omics data that will be the key to unlock the detection and treatment of disease at its earliest stages, when these diseases are most likely to be cured. Unlocking Disease Detection and Treatment with Multi-omics Data: We designed our proprietary multi-omics platform around the most robust approaches to generating proteomic, genomic and metabolomics data at scale, including the use of the Proteograph technology platform from the life science tools company Seer (NASDAQ: SEER) whom PrognomiQ spun out of in 2020.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

Xcell Biosciences (xcellbio) is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell’s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing. For more information, please visit http://www.xcellbio.com/.

Encoded Therapeutics is creating one-time, disease-modifying gene therapies for pediatric central nervous system (CNS) disorders with its cell-selective targeting and regulation platform. The Encoded approach offers potentially unprecedented gene specificity and cell selectivity to unlock novel opportunities by targeting a range of disease mechanisms. Encoded’s technology is compatible with any delivery system to control where and when therapeutic transgenes are expressed, thereby shaping the functionality of target cells and holding broader therapeutic potential beyond CNS disorders. For more information, please visit www.encoded.com, and follow us on LinkedIn, Twitter @EncodedTx and YouTube. Social media guidelines: https://encoded.com/social-media-community-guidelines/

BaseHealth is a next-generation health care analytics company for top health systems and Medicare Advantage plans focused on applying evidence-based expert systems and AI to analyze any type of patient population, improve care management programs, identify risk adjustment payment opportunities, and optimize quality ratings. BaseHealth has built an advanced, scalable enterprise analytics platform on the widest set of data types available, including pioneering uses of laboratory data for value-based care applications. We believe in transparently augmenting what health care providers and plans are currently doing to maximize successful outcomes at reduced costs, helping them achieve greater analytics maturity as organizations, and continuously improving.

We are building the largest longitudinal cohort in the Americas to power precision health at scale for all. Our goal is to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. We are focused on Latin America and our diaspora populations throughout the world including founder populations in the Americas, those who identify as Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander as well as people who self identify as belonging to two or more of these groups. Core to our mission is building trust with the communities we serve and long term partnerships with communities, researchers, clinicians, and most of all patients and their families. This is your biobank and for the benefit of all. If we build it, we can decide how the data are used. And no one is going to do it for us, so let’s roll up our sleeves and “time to build.” Join us! Este biobanco es tuyo y para todo el continente porque si lo construimos juntos podemos decidir cómo se usan los datos y con que fines. Nadie lo va a hacer por nosotros así que bienvenido a nuestro esfuerzo. Unete!

Healthcare data is messy. We all know it. Datasets are often riddled with errors, inconsistencies and missing values, requiring data science teams to spend countless hours cleaning data before analyzing it. The Cornerstone AI assistant is purpose-built to clean RWD. Its proprietary machine learning models automatically generate unique clinically relevant data cleaning rules for every dataset. The Cornerstone AI assistant learns the structure and connections across data sources, harmonizing the structure. ML models then identify and correct errors, which are applied automatically or guided through our UI for optimal balance of scalability and nuance.

Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.

Gencove creates high-volume, cost-sensitive sequencing software-as-a-service to help academic, agriculture, biotech, diagnostic, and pharmaceutical companies get all the genomic information they need to make life-saving discoveries.

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.